PDX Pharma was granted new JP and US patents

We are pleased to report that PDX Pharma has secured intellectual property protection in Japan for the AIRISE (Augmenting Immune Response and Inhibiting Immune Suppressive Environment) family, marking an important milestone in our continued innovation and global IP strategy. This achievement strengthens the AIRISE platform and supports the advancement of in situ cancer vaccination approaches based on our Pdx-NP platform, designed for the co-delivery of anticancer agents and nucleic acid adjuvants.

This news follows our recent success in securing an additional US patent for the ARAC (Antigen Release Agent and Checkpoint inhibitor) family last month (US12,582,658). This patent includes broad claims covering Pdx-NP-based co-delivery of a wide range of anticancer agents and immune checkpoint inhibitors. Both AIRISE and ARAC developments have been funded by the National Cancer Institute.